Literature DB >> 18347229

Screening, treatment, and control of hypertension in US private physician offices, 2003-2004.

Jun Ma1, Randall S Stafford.   

Abstract

Essential hypertension is the most common diagnosis in US primary care settings for middle-aged persons and seniors. Yet, data on hypertension screening, treatment, and control in such settings are limited. We analyzed National Ambulatory Medical Care Survey data to examine the rates of and factors associated with hypertension screening, treatment, and control during US office visits in 2003 and 2004. Blood pressure was measured in 56% (95% confidence limits: 52% to 59%) of all visits by patients > or =18 years of age and in 93% (95% confidence limits: 89% to 96%) of hypertensive patient visits. Among the latter, 62% (95% confidence limits: 55% to 69%) were treated. Diuretics were the most commonly prescribed antihypertensive agents (46%; 95% confidence limits: 41% to 50%), and combination therapy was reported in 58% (95% confidence limits: 54% to 63%) of treated visits. Only 39% (95% confidence limits: 34% to 43%) of treated visits were at recommended blood pressure goals. The odds of not being screened for hypertension were notably greater for visits with a provider other than a primary care physician or cardiologist (10.0; 95% confidence limits: 5.5 to 16.7) and for nonwell care visits (5.6; 95% confidence limits: 3.6 to 8.3). Greater odds of not being treated for hypertension were noted by geographic region (South versus Northeast: 2.6; 95% confidence limits: 1.2 to 5.6) and visit type (first time versus return visits; 1.6; 95% confidence limits: 1.1 to 2.4). The odds of not having blood pressure controlled were greater for patients with comorbidities (1.6; 95% confidence limits: 1.1 to 2.4). In conclusion, more intervention efforts are needed to further reduce the gaps and variations in routine practice in relation to evidence-based practice guidelines for hypertension screening, treatment, and control.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347229      PMCID: PMC2671992          DOI: 10.1161/HYPERTENSIONAHA.107.107086

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  30 in total

1.  ICD-9-CM. International Classification of Diseases, 9th revision, Clinical Modification. 3d edition, volumes 1, 2 and 3. Official authorized addendum effective October 1, 1990--HCFA.

Authors: 
Journal:  J Am Med Rec Assoc       Date:  1990-08

2.  Should mitigating comorbidities be considered in assessing healthcare plan performance in achieving optimal glycemic control?

Authors:  Leonard M Pogach; Anjali Tiwari; Miriam Maney; Mangala Rajan; Donald R Miller; David Aron
Journal:  Am J Manag Care       Date:  2007-03       Impact factor: 2.229

3.  Missed opportunities in preventive counseling for cardiovascular disease--United States, 1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1998-02-13       Impact factor: 17.586

4.  Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States.

Authors:  Randall S Stafford; Veronica Monti; Curt D Furberg; Jun Ma
Journal:  Hypertension       Date:  2006-06-19       Impact factor: 10.190

5.  Improved blood pressure control with a physician-nurse team and home blood pressure measurement.

Authors:  Vincent J Canzanello; Patricia L Jensen; Lora L Schwartz; Joel B Worra; Lois K Klein
Journal:  Mayo Clin Proc       Date:  2005-01       Impact factor: 7.616

6.  How do minor changes in the definition of blood pressure control affect the reported success of hypertension treatment?

Authors:  Beverly B Green; Robert C Kaplan; Bruce M Psaty
Journal:  Am J Manag Care       Date:  2003-03       Impact factor: 2.229

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Diet and physical activity counseling during ambulatory care visits in the United States.

Authors:  Jun Ma; Guido G Urizar; Tseday Alehegn; Randall S Stafford
Journal:  Prev Med       Date:  2004-10       Impact factor: 4.018

9.  Hypertension treatment and control in five European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

10.  Changes in the continuation of antihypertensive drug use after ALLHAT.

Authors:  Fagen Xie; Diana B Petitti; Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-11       Impact factor: 3.738

View more
  22 in total

1.  Quality of US primary care delivered by resident and staff physicians.

Authors:  Leah Zallman; Jun Ma; Lan Xiao; Karen E Lasser
Journal:  J Gen Intern Med       Date:  2010-07-20       Impact factor: 5.128

2.  Instrumental variable methods to assess quality of care the marginal effects of process-of-care on blood pressure change and treatment costs.

Authors:  Puttarin Kulchaitanaroaj; Barry L Carter; Amber M Goedken; Elizabeth A Chrischilles; John M Brooks
Journal:  Res Social Adm Pharm       Date:  2014-08-01

3.  Predicting changes in hypertension control using electronic health records from a chronic disease management program.

Authors:  Jimeng Sun; Candace D McNaughton; Ping Zhang; Adam Perer; Aris Gkoulalas-Divanis; Joshua C Denny; Jacqueline Kirby; Thomas Lasko; Alexander Saip; Bradley A Malin
Journal:  J Am Med Inform Assoc       Date:  2013-09-17       Impact factor: 4.497

Review 4.  Advancing management of hypertension through pharmacogenomics.

Authors:  Julie A Johnson
Journal:  Ann Med       Date:  2012-06       Impact factor: 4.709

5.  Role of Kidneys in Sex Differences in Angiotensin II-Induced Hypertension.

Authors:  Lei Wang; Ximing Wang; Helena Y Qu; Shan Jiang; Jie Zhang; Liying Fu; Jacentha Buggs; Bo Pang; Jin Wei; Ruisheng Liu
Journal:  Hypertension       Date:  2017-10-23       Impact factor: 10.190

Review 6.  Resistant hypertension and hyperaldosteronism.

Authors:  Carolina C Gonzaga; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

7.  Cholesterol treatment with statins: who is left out and who makes it to goal?

Authors:  Peter Franks; Daniel Tancredi; Paul Winters; Kevin Fiscella
Journal:  BMC Health Serv Res       Date:  2010-03-17       Impact factor: 2.655

8.  Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact.

Authors:  Jean-Marie Krzesinski; Eric P Cohen
Journal:  Core Evid       Date:  2010-06-15

9.  Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study.

Authors:  Izel F Sørensen; Ana I Vazquez; Marguerite R Irvin; Peter Sørensen; Barry R Davis; Charles E Ford; Eric Boerwinkle; John H Eckfeldt; Donna K Arnett
Journal:  Pharmacogenet Genomics       Date:  2014-11       Impact factor: 2.089

10.  Will hypertension performance measures used for pay-for-performance programs penalize those who care for medically complex patients?

Authors:  Laura A Petersen; Lechauncy D Woodard; Louise M Henderson; Tracy H Urech; Kenneth Pietz
Journal:  Circulation       Date:  2009-06-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.